Trovagene (NASDAQ: TROV) reported Q1 EPS of ($0.36), $0.07 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $260 thousand.

For earnings history and earnings-related data on Trovagene (TROV) click here.